Paschalis A, Sheehan B, Riisnaes R, Rodrigues DN, Gurel B, Bertan C, et al. Prostate-specific membrane Antigen Heterogeneity and DNA repair defects in prostate cancer. Eur Urol. 2019;76(4):469–78. https://doi.org/10.1016/j.eururo.2019.06.030.
Article CAS PubMed PubMed Central Google Scholar
Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91(3):528–39. https://doi.org/10.1002/jcb.10661.
Article CAS PubMed Google Scholar
Virgolini I, Decristoforo C, Haug A, Fanti S, Uprimny C. Current status of theranostics in prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45(3):471–95. https://doi.org/10.1007/s00259-017-3882-2.
Gafita A, Rauscher I, Weber M, Hadaschik B, Wang H, Armstrong WR, et al. Novel framework for treatment response evaluation using PSMA PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study. J Nucl Med. 2022;63(11):1651–8. https://doi.org/10.2967/jnumed.121.263072.
Article CAS PubMed PubMed Central Google Scholar
Michalski K, Klein C, Brueggemann T, Meyer PT, Jilg CA, Ruf J. Assessing response to [(177)Lu]PSMA radioligand therapy using modified PSMA PET progression criteria. J Nucl Med. 2021;62(12):1741–6. https://doi.org/10.2967/jnumed.120.260836.
Article CAS PubMed PubMed Central Google Scholar
Yadav MP, Ballal S, Bal C, Sahoo RK, Damle NA, Tripathi M, et al. Efficacy and safety of 177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients. Clin Nucl Med. 2020;45(1):19–31. https://doi.org/10.1097/rlu.0000000000002833.
Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091–103. https://doi.org/10.1056/NEJMoa2107322.
Article CAS PubMed PubMed Central Google Scholar
Heck MM, Retz M, D’Alessandria C, Rauscher I, Scheidhauer K, Maurer T, et al. Systemic radioligand therapy with (177)Lu labeled prostate specific membrane antigen ligand for imaging and therapy in patients with metastatic castration resistant prostate cancer. J Urol. 2016;196(2):382–91. https://doi.org/10.1016/j.juro.2016.02.2969.
Article CAS PubMed Google Scholar
Fendler WP, Reinhardt S, Ilhan H, Delker A, Böning G, Gildehaus FJ, et al. Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer. Oncotarget. 2017;8(2):3581–90. https://doi.org/10.18632/oncotarget.12240.
Manafi-Farid R, Harsini S, Saidi B, Ahmadzadehfar H, Herrmann K, Briganti A, et al. Factors predicting biochemical response and survival benefits following radioligand therapy with [177Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review. Eur J Nucl Med Mol Imaging. 2021;48(12):4028–41. https://doi.org/10.1007/s00259-021-05237-y.
Article CAS PubMed PubMed Central Google Scholar
Heidegger I, Kesch C, Kretschmer A, Tsaur I, Ceci F, Valerio M, et al. Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer—a state of the art review. Ther Adv Med Oncol. 2022;14:17588359221081922. https://doi.org/10.1177/17588359221081922.
Article PubMed PubMed Central Google Scholar
Sandhu S, Guo C, Hofman MS. Radionuclide Therapy in Prostate Cancer: from standalone to combination PSMA theranostics. J Nucl Med. 2021;62(12):1660–8. https://doi.org/10.2967/jnumed.120.243295.
Article CAS PubMed PubMed Central Google Scholar
Ruigrok EAM, van Vliet N, Dalm SU, de Blois E, van Gent DC, Haeck J, et al. Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy. Eur J Nucl Med Mol Imaging. 2021;48(5):1339–50. https://doi.org/10.1007/s00259-020-05057-6.
Article CAS PubMed Google Scholar
Ruigrok EAM, Tamborino G, de Blois E, Roobol SJ, Verkaik N, De Saint-Hubert M, et al. In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T. Eur J Nucl Med Mol Imaging. 2022;49(11):3627–38. https://doi.org/10.1007/s00259-022-05821-w.
Article CAS PubMed PubMed Central Google Scholar
Violet J, Jackson P, Ferdinandus J, Sandhu S, Akhurst T, Iravani A, et al. Dosimetry of (177)Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes. J Nucl Med. 2019;60(4):517–23. https://doi.org/10.2967/jnumed.118.219352.
Article CAS PubMed Google Scholar
Peters SMB, Privé BM, de Bakker M, de Lange F, Jentzen W, Eek A, et al. Intra-therapeutic dosimetry of [(177)Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome. Eur J Nucl Med Mol Imaging. 2022;49(2):460–9. https://doi.org/10.1007/s00259-021-05471-4.
Article CAS PubMed Google Scholar
Upton RN, Mould DR. Basic concepts in population modeling, simulation, and model-based drug development: part 3-introduction to pharmacodynamic modeling methods. CPT Pharmacometrics Syst Pharmacol. 2014;3(1):e88. https://doi.org/10.1038/psp.2013.71.
Article CAS PubMed PubMed Central Google Scholar
McMahon SJ. The linear quadratic model: usage, interpretation and challenges. Phys Med Biol. 2019;64(1):01TR. https://doi.org/10.1088/1361-6560/aaf26a.
Meibohm B, Derendorf H. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. Int J Clin Pharmacol Ther. 1997;35(10):401–13.
Zou H, Banerjee P, Leung SSY, Yan X. Application of pharmacokinetic-pharmacodynamic modeling in drug delivery: development and challenges. Front Pharmacol. 2020;11:997. https://doi.org/10.3389/fphar.2020.00997.
Article CAS PubMed PubMed Central Google Scholar
Heck MM, Tauber R, Schwaiger S, Retz M, D’Alessandria C, Maurer T, et al. Treatment outcome, toxicity, and predictive factors for radioligand therapy with (177)Lu-PSMA-I&T in metastatic castration-resistant prostate cancer. Eur Urol. 2019;75(6):920–6. https://doi.org/10.1016/j.eururo.2018.11.016.
Article CAS PubMed Google Scholar
Khreish F, Ghazal Z, Marlowe RJ, Rosar F, Sabet A, Maus S, et al. 177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study). Eur J Nucl Med Mol Imaging. 2022;49(3):1075–85. https://doi.org/10.1007/s00259-021-05525-7.
Article CAS PubMed Google Scholar
Peters SMB, Meyer Viol SL, van der Werf NR, de Jong N, van Velden FHP, Meeuwis A, et al. Variability in lutetium-177 SPECT quantification between different state-of-the-art SPECT/CT systems. EJNMMI Phys. 2020;7(1):9. https://doi.org/10.1186/s40658-020-0278-3.
Article PubMed PubMed Central Google Scholar
Siebinga H, Privé BM, Peters SMB, Nagarajah J, Dorlo TPC, Huitema ADR, et al. Population pharmacokinetic dosimetry model using imaging data to assess variability in pharmacokinetics of (177) Lu-PSMA-617 in prostate cancer patients. CPT Pharmacomet Syst Pharmacol. 2023;12(8):1060–71. https://doi.org/10.1002/psp4.12914.
Kletting P, Kull T, Maass C, Malik N, Luster M, Beer AJ, et al. Optimized peptide amount and activity for (9)(0)Y-labeled DOTATATE therapy. J Nucl Med. 2016;57(4):503–8. https://doi.org/10.2967/jnumed.115.164699.
Article CAS PubMed Google Scholar
Rinscheid A, Kletting P, Eiber M, Beer AJ, Glatting G. Technical Note: Optimal sampling schedules for kidney dosimetry based on the hybrid planar/SPECT method in (177) Lu-PSMA therapy. Med Phys. 2019;46(12):5861–6. https://doi.org/10.1002/mp.13846.
Article CAS PubMed Google Scholar
Weineisen M, Schottelius M, Simecek J, Baum RP, Yildiz A, Beykan S, et al. 68Ga- and 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med. 2015;56(8):1169–76. https://doi.org/10.2967/jnumed.115.158550.
Article CAS PubMed Google Scholar
Gaertner FC, Halabi K, Ahmadzadehfar H, Kürpig S, Eppard E, Kotsikopoulos C, et al. Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer. Oncotarget. 2017;8(33):55094–103. https://doi.org/10.18632/oncotarget.19049.
Article PubMed PubMed Central Google Scholar
Begum NJ, Thieme A, Eberhardt N, Tauber R, D’Alessandria C, Beer AJ, et al. The effect of total tumor volume on the biologically effective dose to tumor and kidneys for (177)Lu-labeled PSMA peptides. J Nucl Med. 2018;59(6):929–33. https://doi.org/10.2967/jnumed.117.203505.
Article CAS PubMed Google Scholar
Gafita A, Wang H, Robertson A, Armstrong WR, Zaum R, Weber M, et al. Tumor sink effect in (68)Ga-PSMA-11 PET: Myth or reality? J Nucl Med. 2022;63(2):226–32. https://doi.org/10.2967/jnumed.121.261906.
Article CAS PubMed PubMed Central Google Scholar
Siebinga H, Heuvel JO, Rijkhorst EJ, Hendrikx J, de Wit-van der Veen BJ. The impact of peptide amount on tumor uptake to assess psma receptor saturation on (68)Ga-PSMA-11 PET/CT in patients with primary prostate cancer. J Nucl Med. 2023;64(1):63–8. https://doi.org/10.2967/jnumed.122.264101.
留言 (0)